U.S. launches extensive Alzheimer's studies

U.S. launches extensive alzheimer's studies
5-year, $55 million effort will look at exercise, drug treatment as therapies for early disease.

(HealthDay)—Four U.S. government-funded clinical trials will search for new therapies for Alzheimer's disease.

The five-year effort will look at drug and exercise treatments for patients with early stage disease, test if the prazosin can reduce agitation in Alzheimer's patients, and examine a new approach to speed testing of drugs in .

The trials, which could cost as much as $55 million, are projects of the Alzheimer's Disease Cooperative Study (ADCS), a of and clinics established in 1991 by the U.S. National Institutes of Health.

The consortium, which includes more than 70 sites in the United States and Canada, focuses on research of diagnosis and treatment methods that might not be tested by the drug industry.

The four studies are among efforts to accomplish the research goals outlined in the National Plan to Address Alzheimer's Disease, which was announced in May 2012. The plan calls for a coordinated and focused effort in research, care and services for Alzheimer's and related types of . The goal is to find ways to prevent and effectively treat Alzheimer's by 2025.

"The ADCS is a key initiative in the federal program to discover, develop and test new Alzheimer's treatments and . Over the years, it has proved invaluable in advancing our understanding about the disease and how to conduct research in this challenging area," Dr. Richard Hodes, director of the National Institute on Aging, said in an NIH news release.

"I am particularly excited that this round of studies will use what we have learned by testing interventions pre-symptomatically, as early as we can in the development of the disease, where we now think the best hope lies for keeping Alzheimer's at bay," he added.

More information: The Alzheimer's Association has more about Alzheimer's disease.

add to favorites email to friend print save as pdf

Related Stories

Pfizer and J&J end development of Alzheimer's drug

Aug 06, 2012

Pfizer Inc. and Johnson & Johnson say they are ending development of a once-promising drug designed to treat Alzheimer's disease after the treatment failed in two late-stage clinical trials.

Recommended for you

Cold sores increase the risk of dementia

Oct 20, 2014

Infection with herpes simplex virus increases the risk of Alzheimer's disease. Researchers at Umeå University, Sweden, claim this in two studies in the journal Alzheimer's & Dementia.

World first effort to prevent dementia in high-risk people

Oct 15, 2014

Dementia will soon engulf more than 100 million people across the globe, but an international research group is leading a world-first effort to prevent dementia in people who are at high risk of this insidious disease.

User comments